2021
PCSK9 Inhibiting Monoclonal Antibodies
Ahmed Z, Juthani P, Lee M, Desai N. PCSK9 Inhibiting Monoclonal Antibodies. Stroke Revisited 2021, 125-133. DOI: 10.1007/978-981-16-3923-4_11.Peer-Reviewed Original ResearchProprotein convertase subtilisin/kexin type 9Lipid-lowering medicationsSubset of patientsIschemic strokeLower PCSK9Low-density lipoprotein cholesterolConvertase subtilisin/kexin type 9Subtilisin/kexin type 9Monoclonal antibodiesCoenzyme A (HMG-CoA) reductase inhibitorsComponents of dyslipidemiaHigh-intensity statinsStroke risk reductionModifiable risk factorsHealthy lifestyle modificationsLDL-C levelsRisk of strokeStatin-induced myopathyTreatment of hyperlipidemiaA Reductase InhibitorsLifestyle modificationStatin useLipoprotein cholesterolPCSK9 inhibitorsStroke outcome
2019
Management of Hyperlipidemia After Stroke
Brooks DC, Schindler JL. Management of Hyperlipidemia After Stroke. Current Treatment Options In Cardiovascular Medicine 2019, 21: 93. PMID: 31840196, DOI: 10.1007/s11936-019-0774-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsManagement of hyperlipidemiaKey therapeutic targetCardiovascular diseaseTherapeutic targetAggressive LDL-C reductionStroke risk reductionLDL-C reductionAtherosclerotic vascular diseaseAvailable treatment optionsGeneral cardiovascular diseaseRecent FindingsStatinsIschemic strokePCSK9 inhibitorsHemorrhagic strokeRisk modificationTreatment optionsVascular diseaseRecent trialsNovel agentsNew agentsMost subtypesHyperlipidemiaStrokePatientsDisease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply